#602: Avoidant/Restrictive Food Intake Disorder (ARFID) – Megan Hellner, DrPH, RD & Katherine Hill, MD

Key Takeaways

• ARFID affects all body sizes, not just underweight individuals
• Often misdiagnosed as picky eating, leading to delayed treatment
• Athletes with ARFID risk low energy availability and RED‑S
• Evidence‑based treatment combines nutrition rehab, exposure therapy, multidisciplinary care
• Early screening in primary care can prevent long‑term medical complications

Pulse Analysis

Avoidant/Restrictive Food Intake Disorder (ARFID) is gaining visibility beyond traditional eating‑disorder circles, as clinicians recognize its prevalence across the weight spectrum. Unlike anorexia or bulimia, ARFID is driven by sensory sensitivities, fear of consequences, or a lack of interest in food, making it easy to mistake for ordinary pickiness. This diagnostic nuance matters for primary‑care physicians and pediatricians, who are now urged to incorporate targeted screening questions into routine visits. Early identification not only averts nutritional deficiencies but also curtails downstream costs associated with chronic medical interventions.

The disorder’s impact on athletes underscores a critical intersection between sports nutrition and clinical psychology. When restrictive eating patterns limit dietary variety, athletes may develop low energy availability, mirroring the Relative Energy Deficiency in Sport (RED‑S) syndrome. Such conditions compromise performance, increase injury risk, and can lead to long‑term bone health issues. Integrating ARFID protocols into sports medicine practices—through multidisciplinary teams that include dietitians, psychologists, and physicians—creates a market niche for specialized treatment centers and tele‑health platforms, driving innovation in the health‑tech sector.

Research gaps remain, particularly around standardized assessment tools and long‑term outcome data. Funding bodies and private investors are showing interest in developing evidence‑based digital therapeutics that deliver exposure‑based interventions and nutrition counseling at scale. As the healthcare industry shifts toward value‑based care, demonstrating cost‑effectiveness of comprehensive ARFID programs will be pivotal. Stakeholders who invest in training, technology, and research now stand to shape a growing segment of the eating‑disorder treatment market.